Skip to content
0231 / 141 237kontakt@diabeteszentrum-doc.deKampstraße 45, 44137 Dortmund
Diabeteszentrum Dortmund
Book an appointmentAppointment

Clinical research

Clinical trials unit

New studies open up new treatment options. Participants can get to know new medicines – often used in everyday medical practice only years later – before they reach the market.

Why take part?

Access to the therapies of tomorrow

As an experienced trials unit we enable our patients to take part in international clinical studies – with the closest medical supervision.

  • Early access to innovation

    You gain access to new active substances that are often only available to the wider public years later.

  • Intensive supervision

    Study participants are closely supervised by our experienced trials team – with regular examinations and personal contact.

  • Expense allowance

    Participants receive an allowance for their time and their contribution to medical research.

How taking part in a study works

It is important to us that you receive answers to all the questions that matter to you before you take part in a clinical study. That is why every participation is preceded by several conversations with you.

How a study works

Current study

Participation possible

MARITIME-CV

Clinical study for people with cardiovascular disease and overweight/obesity – active substance: maridebart cafraglutide (AMG 133)

  • GLP-1 activation + GIP inhibition
  • International
  • With/without type 2 diabetes
  • From 45 years of age
  • Monthly injection

Who can take part?

  • Men and women aged 45 and over
  • BMI ≥ 27 kg/m²
  • Confirmed atherosclerotic cardiovascular disease (ASCVD), e.g. heart attack, ischaemic stroke, peripheral arterial disease, ABI < 0.9, amputation caused by atherosclerosis
  • With or without type 2 diabetes

What to expect

  • Monthly injection – maridebart cafraglutide or placebo
  • Dosing schedule over 16 weeks, then a monthly maintenance dose
  • Regular checks: blood pressure, laboratory values, weight, ECG
  • Participation for about 3 years (double-blind) + optionally 2 years open-label
  • Close medical supervision by our trials unit
  • Expense allowance for participants

Aim of the study

The study examines whether maridebart cafraglutide reduces the risk of serious cardiovascular events and improves metabolism in the long term:

  • Lower risk of heart attack, stroke and cardiovascular death
  • Fewer hospital stays and vascular procedures
  • Improvement in weight, blood pressure and blood glucose
  • Reduction of inflammatory markers

How it works

Maridebart cafraglutide belongs to an innovative class of substances that activates GLP-1 and inhibits GIP at the same time – with the aim of reducing weight, improving metabolism and having a positive effect on cardiovascular disease.

Interested? We are happy to inform you without obligation.

Together we check whether taking part is an option for you.

0231 / 141 237Send an email

Completed studies

Participation no longer possible

  • 2023

    PREVAIL-Studie

    Closed
    Obicetrapib

    Clinical study for people with cardiovascular disease and elevated LDL cholesterol. It examines whether obicetrapib lowers the risk of heart attack, stroke and serious cardiovascular events – in addition to statin therapy.

    • Aged 18 and over with known cardiovascular disease
    • LDL cholesterol elevated despite statin treatment
    • Taken daily (tablet)

  • 2024

    Baxdrostat (CIN-107)

    Closed
    Baxdrostat

    Clinical study for people with hard-to-control high blood pressure. It assesses efficacy and safety in arterial hypertension that is insufficiently controlled despite existing medication.

    • Aged 18 and over with diagnosed arterial hypertension
    • Blood pressure ≥ 140/90 mmHg despite 2–3 medicines
    • Taken daily (tablet)

  • 2024

    REDEFINE-Studie

    Closed
    CagriSema

    International study for people with type 2 diabetes and cardiovascular disease. It examines the effects of CagriSema on blood glucose, weight and cardiovascular health.

    • Aged 18 and over, BMI ≥ 27, with/without type 2 diabetes
    • Existing cardiovascular disease
    • Weekly injection, duration about 1 year

  • 2024

    REIMAGINE 2-Studie

    Closed
    CagriSema

    Study for people with type 2 diabetes. It examines how well CagriSema lowers blood glucose and supports weight loss – compared with semaglutide, cagrilintide or placebo.

    • Aged 18 and over with type 2 diabetes, BMI ≥ 27
    • Treatment with metformin, with/without an SGLT2 inhibitor
    • Weekly injection over several months

Taking part

Interested in taking part in a study?

We will inform you without obligation about ongoing studies and check together with you whether taking part is an option.

Book onlineOnline courses

Reachable by phone

0231 / 141 237

Mon, Tue, Thu 08:00–12:00 & 13:30–17:00

Wed 08:00–12:00 · Fri 08:00–12:30

Write an email